Molbio Diagnostics · risk themes across the available quarters.
Bear-case history
Historical device sales range 2200-2600 annually; Q1 FY27 at 164 devices appears seasonally weak but raises questions about whether the addressable market is saturating in core TB programs. Management deflected on explaining the volume realization decline.
Management acknowledged they cannot provide specific volume guidance for the HPV national program at this stage, deferring to next quarter. This represents unquantified revenue upside at a company trading at IPO valuations.
Digital pathology subsidiary expected to remain loss-making through FY27, creating a ~9 crore annual drag at the PAT level while consuming management bandwidth during critical US market entry.
~90% of domestic revenue tied to government TB program creates dependency on funding allocations, tender pricing, and political prioritization. Any policy shift or budget constraint could materially impact results.
Export revenue at ~16% of total is volatile (described as 'up and down') and management acknowledged 3-year ramp-up timeline with registrations ongoing across 90+ countries. No clear acceleration path articulated.